Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Visceral fat dysfunction is positively associated with hypogonadism in Chinese men.

Scientific reports·2016
Same author

Fingerprint Analysis of Desmodium Triquetrum L. Based on Ultra Performance Liquid Chromatography with Photodiode Array Detector Combined with Chemometrics Methods.

Journal of chromatographic science·2016
Same author

Neck circumference as an independent indicator to non-alcoholic fatty liver disease in non-obese men.

Nutrition & metabolism·2016
Same author

Associations between implementation characteristics and evidence-based practice sustainment: a study of the Adolescent Community Reinforcement Approach.

Implementation science : IS·2015
Same author

A pre-post pilot study of peer nutritional counseling and food insecurity and nutritional outcomes among antiretroviral therapy patients in Honduras.

BMC nutrition·2015
Same author

MAPKs and Hsc70 are critical to the protective effect of molecular hydrogen during the early phase of acute pancreatitis.

The FEBS journal·2015

Related Experiment Video

Updated: Jun 24, 2025

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.6K

CG001, a C3b-targeted complement inhibitor, blocks 3 complement pathways: development and preclinical evaluation.

Ling Li1, Peipei Ding1, Yanrong Dong2

  • 1Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.

Blood Advances
|June 12, 2024
PubMed
Summary

A novel fusion protein, CG001, potently inhibits all three complement pathways by targeting C3b. This complement inhibitor demonstrated therapeutic effects in disease models and showed a favorable safety profile in preclinical evaluations.

More Related Videos

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.9K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

Related Experiment Videos

Last Updated: Jun 24, 2025

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.6K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.9K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

Area of Science:

  • Immunology
  • Biochemistry
  • Drug Development

Background:

  • Dysregulated complement activation is implicated in numerous human diseases.
  • There is a growing need for effective complement inhibitors to treat these conditions.

Purpose of the Study:

  • To develop a novel, potent inhibitor targeting all three complement pathways.
  • To evaluate the therapeutic efficacy and safety of the developed inhibitor, CG001.

Main Methods:

  • Development of a human-derived fusion protein (CRIg-FH-Fc)x2, termed CG001, targeting C3b.
  • Assessment of CG001's inhibitory activity across all complement pathways.
  • Evaluation of therapeutic effects in mouse and rat models of complement-mediated diseases.
  • Pharmacological and toxicological assessments in rats and cynomolgus monkeys.

Main Results:

  • CG001 potently inhibited all three complement pathways by synergistically binding to C3b via CRIg and Factor H domains.
  • The fusion protein demonstrated therapeutic efficacy in models of hemolytic anemia and glomerulonephritis.
  • Preclinical studies revealed an antibody-like pharmacokinetic profile and no observable toxic effects.

Conclusions:

  • CG001 is a potent, dual-acting complement inhibitor with a promising safety profile.
  • The developed fusion protein exhibits substantial potential for clinical applications in complement-mediated diseases.